HKD21.55
1.37% today
Hong Kong, Dec 30, 09:08 am CET
ISIN
CNE100000FN7
Symbol
1099
Index
Sector
Industry

Sinopharm Group Target price 2024 - Analyst rating & recommendation

Sinopharm Group Classifications & Recommendation:

Buy
69%
Hold
25%
Sell
6%

Sinopharm Group Price Target

Target Price HKD23.36
Price HKD21.55
Potential
Number of Estimates 13
13 Analysts have issued a price target Sinopharm Group 2025 . The average Sinopharm Group target price is HKD23.36. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 11 Analysts recommend Sinopharm Group to buy, 4 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sinopharm Group stock has an average upside potential 2025 of . Most analysts recommend the Sinopharm Group stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Billion HKD 659.21 640.85
2.67% 2.78%
EBITDA Margin 4.38% 3.77%
7.21% 14.00%
Net Margin 1.52% 1.42%
1.68% 6.55%

15 Analysts have issued a sales forecast Sinopharm Group 2024 . The average Sinopharm Group sales estimate is

HKD641b
Unlock
. This is
0.33% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD651b 1.99%
Unlock
, the lowest is
HKD635b 0.53%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 HKD659b 2.67%
2024
HKD641b 2.78%
Unlock
2025
HKD684b 6.80%
Unlock
2026
HKD732b 6.93%
Unlock
2027
HKD812b 10.99%
Unlock

13 Analysts have issued an Sinopharm Group EBITDA forecast 2024. The average Sinopharm Group EBITDA estimate is

HKD24.1b
Unlock
. This is
10.78% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD28.5b 5.33%
Unlock
, the lowest is
HKD16.6b 38.82%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 HKD28.9b 4.73%
2024
HKD24.1b 16.43%
Unlock
2025
HKD25.9b 7.25%
Unlock
2026
HKD27.6b 6.63%
Unlock
2027
HKD19.9b 27.95%
Unlock

EBITDA Margin

2023 4.38% 7.21%
2024
3.77% 14.00%
Unlock
2025
3.78% 0.27%
Unlock
2026
3.77% 0.26%
Unlock
2027
2.45% 35.01%
Unlock

7 Sinopharm Group Analysts have issued a net profit forecast 2024. The average Sinopharm Group net profit estimate is

HKD9.1b
Unlock
. This is
2.85% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HKD9.9b 5.25%
Unlock
, the lowest is
HKD8.8b 6.38%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 HKD10.0b 0.94%
2024
HKD9.1b 9.21%
Unlock
2025
HKD9.9b 8.53%
Unlock
2026
HKD11.0b 11.71%
Unlock

Net Margin

2023 1.52% 1.68%
2024
1.42% 6.55%
Unlock
2025
1.44% 1.41%
Unlock
2026
1.51% 4.86%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share HKD 3.21 2.91
0.94% 9.35%
P/E 7.50
EV/Sales 0.32

7 Analysts have issued a Sinopharm Group forecast for earnings per share. The average Sinopharm Group <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

HKD2.91
Unlock
. This is
3.00% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
HKD3.16 5.33%
Unlock
, the lowest is
HKD2.81 6.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 HKD3.21 0.94%
2024
HKD2.91 9.35%
Unlock
2025
HKD3.16 8.59%
Unlock
2026
HKD3.53 11.71%
Unlock

P/E ratio

Current 7.28 22.97%
2024
7.50 3.02%
Unlock
2025
6.91 7.87%
Unlock
2026
6.18 10.56%
Unlock

Based on analysts' sales estimates for 2024, the Sinopharm Group stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.32 10.34%
2024
0.32 0.56%
Unlock
2025
0.30 6.37%
Unlock
2026
0.28 6.47%
Unlock
2027
0.25 9.90%
Unlock

P/S ratio

Current 0.11 19.46%
2024
0.11 0.37%
Unlock
2025
0.10 6.39%
Unlock
2026
0.09 6.43%
Unlock
2027
0.08 9.98%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today